Impaired functional connectivity of brain reward circuitry in patients with schizophrenia and cannabis use disorder: Effects of cannabis and THC

Schizophrenia Research

Volumn 158, Issue 1-3, 2014, Pages 176-182

  Fischer, Adina S ^a   Whitfield Gabrieli, Susan ^b   Roth, Robert M ^a   Brunette, Mary F ^a   Green, Alan I ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Brain reward circuitry; Cannabis use disorder; FMRI; Nucleus accumbens; Resting state functional connectivity; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; CANNABIS; CHLORPROMAZINE; DRONABINOL; HALOPERIDOL; OLANZAPINE; PALIPERIDONE; RISPERIDONE; CANNABINOID RECEPTOR AGONIST;

ADULT; ANTERIOR CINGULATE; ANTERIOR PREFRONTAL CORTEX; ARTICLE; BRAIN CORTEX; BRAIN REWARD CIRCUIT; CANNABIS ADDICTION; CANNABIS SMOKING; CLINICAL ARTICLE; COMPARATIVE STUDY; CONNECTOME; CONTROLLED STUDY; DISEASE ASSOCIATION; FALSE POSITIVE RESULT; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HUMAN; IMAGE ANALYSIS; INSULA; MALE; NERVOUS SYSTEM PARAMETERS; NEUROIMAGING; NUCLEUS ACCUMBENS; ORBITAL CORTEX; PARAHIPPOCAMPAL CORTEX; PATHOLOGICAL ANATOMY; PILOT STUDY; PREDICTIVE VALUE; PREFRONTAL CORTEX; PREMOTOR CORTEX; PRIORITY JOURNAL; QUALITY CONTROL; RESTING STATE FUNCTIONAL CONNECTIVITY; RESTING STATE NETWORK; REWARD; SCHIZOPHRENIA; ADDICTION; BLOOD; BRAIN; BRAIN MAPPING; COMPLICATION; DRUG EFFECTS; NERVE TRACT; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; REST;

ADMINISTRATION, ORAL; ADULT; BRAIN; BRAIN MAPPING; CANNABINOID RECEPTOR AGONISTS; CANNABIS; DRONABINOL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MARIJUANA SMOKING; NEURAL PATHWAYS; PILOT PROJECTS; REST; REWARD; SCHIZOPHRENIA; SUBSTANCE-RELATED DISORDERS;

EID: 84906936544     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2014.04.033     Document Type: Article

References (45)

1. Behzadi Y., Restom K., Liau J., Liu T.T. A component based noise correction method (CompCor) for BOLD and perfusion based fMRI. NeuroImage 2007, 37(1):90-101.
2. Benowitz N.L., Hukkanen J., Jacob P.I. Nicotine chemistry, metabolism, kinetics, and biomarkers. Handbook of Experimental Pharmacology 2009, 29-59. Springer-Verlag, Berlin, Heidelberg. J.E. Henningfield (Ed.).
3. Bhattacharyya S., Fusar-Poli P., Borgwardt S., Martin-Santos R., Nosarti C., O'Carroll C., Allen P., Seal M.L., Fletcher P.C., Crippa J.A., Giampietro V., Mechelli A., Atakan Z., McGuire P. Modulation of mediotemporal and ventrostriatal function in humans by delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch. Gen. Psychiatry 2009, 66(4):442-451.
4. Buckley P.F., Miller B.J., Lehrer D.S., Castle D.J. Psychiatric comorbidities and schizophrenia. Schizophr. Bull. 2009, 35(2):383-402.
5. Budney A.J., Novy P.L., Hughes J.R. Marijuana withdrawal among adults seeking treatment for marijuana dependence. Addiction 1999, 94(9):1311-1322.
6. Cauda F., Cavanna A.E., D'Agata F., Sacco K., Duca S., Geminiani G.C. Functional connectivity and coactivation of the nucleus accumbens: a combined functional connectivity and structure-based meta-analysis. J. Cogn. Neurosci. 2011, 23(10):2864-2877.
7. Chai X.J., Castanon A.N., Ongur D., Whitfield-Gabrieli S. Anticorrelations in resting state networks without global signal regression. NeuroImage 2012, 59(2):1420-1428.
8. Chambers R.A., Krystal J.H., Self D.W. A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol. Psychiatry 2001, 50(2):71-83.
9. Di Martino A., Scheres A., Margulies D.S., Kelly A.M., Uddin L.Q., Shehzad Z., Biswal B., Walters J.R., Castellanos F.X., Milham M.P. Functional connectivity of human striatum: a resting state FMRI study. Cereb. Cortex 2008, 18(12):2735-2747.
10. Drake R.E., Xie H., McHugo G.J., Green A.I. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr. Bull. 2000, 26(2):441-449.
11. Esslinger C., Englisch S., Inta D., Rausch F., Schirmbeck F., Mier D., Kirsch P., Meyer-Lindenberg A., Zink M. Ventral striatal activation during attribution of stimulus saliency and reward anticipation is correlated in unmedicated first episode schizophrenia patients. Schizophr. Res. 2012, 140(1-3):114-121.
12. First M.B., Spitzer R.L., Gibbon M., Williams J.B.W. Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID-I/P) 2002, American Psychiatric Publishing, Inc., Washington, D.C. Patient edition.
13. Foltin R.W., Brady J.V., Fischman M.W., Emurian C.S., Dominitz J. Effects of smoked marijuana on social interaction in small groups. Drug Alcohol Depend. 1987, 20(1):87-93.
14. Fornito A., Yucel M., Wood S.J., Bechdolf A., Carter S., Adamson C., Velakoulis D., Saling M.M., McGorry P.D., Pantelis C. Anterior cingulate cortex abnormalities associated with a first psychotic episode in bipolar disorder. Br. J. Psychiatry 2009, 194(5):426-433.
15. Fox M.D., Raichle M.E. Spontaneous fluctuations in brain activity observed with functional magnetic resonance imaging. Nat. Rev. Neurosci. 2007, 8(9):700-711.
16. Gardner E.L. Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol. Biochem. Behav. 2005, 81(2):263-284.
17. Grant I., Atkinson J.H., Gouaux B., Wilsey B. Medical marijuana: clearing away the smoke. Open Neurol. J. 2012, 6:18-25.
18. Green A.I., Zimmet S.V., Strous R.D., Schildkraut J.J. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine?. Harv. Rev. Psychiatry 1999, 6(6):287-296.
19. Green A.I., Burgess E.S., Dawson R., Zimmet S.V., Strous R.D. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr. Res. 2003, 60(1):81-85.
20. Green A.I., Noordsy D.L., Brunette M.F., O'Keefe C. Substance abuse and schizophrenia: pharmacotherapeutic intervention. J. Subst. Abus. Treat. 2008, 34:61-71.
21. Heerey E.A., Robinson B.M., McMahon R.P., Gold J.M. Delay discounting in schizophrenia. Cogn. Neuropsychiatry 2007, 12(3):213-221.
22. Heishman S.J., Singleton E.G., Liguori A. Marijuana Craving Questionnaire: development and initial validation of a self-report instrument. Addiction 2001, 96(7):1023-1034.
23. Henquet C., Murray R., Linszen D., van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr. Bull. 2005, 31(3):608-612.
24. Henquet C., van Os J., Kuepper R., Delespaul P., Smits M., Campo J.A., Myin-Germeys I. Psychosis reactivity to cannabis use in daily life: an experience sampling study. Br. J. Psychiatry 2010, 196(6):447-453.
25. Hides L., Dawe S., Kavanagh D.J., Young R.M. Psychotic symptom and cannabis relapse in recent-onset psychosis. Prospective study. Br. J. Psychiatry 2006, 189:137-143.
26. Hjorthoj C., Fohlmann A., Nordentoft M. Treatment of cannabis use disorders in people with schizophrenia spectrum disorders - a systematic review. Addict. Behav. 2009, 34(6-7):520-525.
27. Huestis M.A. Pharmacokinetics and metabolism of the plant cannabinoids, delta9-tetrahydrocannabinol, cannabidiol and cannabinol. Handb. Exp. Pharmacol. 2005, (168):657-690.
28. Juckel G., Schlagenhauf F., Koslowski M., Wustenberg T., Villringer A., Knutson B., Wrase J., Heinz A. Dysfunction of ventral striatal reward prediction in schizophrenia. NeuroImage 2006, 29(2):409-416.
29. Juckel G., Friedel E., Koslowski M., Witthaus H., Ozgurdal S., Gudlowski Y., Knutson B., Wrase J., Brune M., Heinz A., Schlagenhauf F. Ventral striatal activation during reward processing in subjects with ultra-high risk for schizophrenia. Neuropsychobiology 2012, 66(1):50-56.
30. Kalman D., Morissette S.B., George T.P. Co-morbidity of smoking in patients with psychiatric and substance use disorders. Am. J. Addict. 2005, 14(2):106-123.
31. Kay S.R., Fiszbein A., Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276.
32. Koethe D., Gerth C.W., Neatby M.A., Haensel A., Thies M., Schneider U., Emrich H.M., Klosterkotter J., Schultze-Lutter F., Leweke F.M. Disturbances of visual information processing in early states of psychosis and experimental delta-9-tetrahydrocannabinol altered states of consciousness. Schizophr. Res. 2006, 88(1-3):142-150.
33. Krystal J.H., D'Souza D.C., Gallinat J., Driesen N., Abi-Dargham A., Petrakis I., Heinz A., Pearlson G. The vulnerability to alcohol and substance abuse in individuals diagnosed with schizophrenia. Neurotox. Res. 2006, 10(3-4):235-252.
34. Moberg P.J., Arnold S.E., Doty R.L., Kohler C., Kanes S., Seigel S., Gur R.E., Turetsky B.I. Impairment of odor hedonics in men with schizophrenia. Am. J. Psychiatry 2003, 160(10):1784-1789.
35. Nielsen M.O., Rostrup E., Wulff S., Bak N., Lublin H., Kapur S., Glenthoj B. Alterations of the brain reward system in antipsychotic naive schizophrenia patients. Biol. Psychiatry 2012, 71(10):898-905.
36. Oleson E.B., Cheer J.F. A brain on cannabinoids: the role of dopamine release in reward seeking. Cold Spring Harb. Perspect. Med. 2012, 2(8).
37. Raichle M.E. The restless brain. Brain Connect. 2011, 1(1):3-12.
38. Roth R.M., Brunette M.F., Green A.I. Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism?. Curr. Psychiatry Rep. 2005, 7(4):283-291.
39. Sobell L.C., Brown J., Leo G.I., Sobell M.B. The reliability of the Alcohol Timeline Follow-Back when administered by telephone and by computer. Drug Alcohol Depend. 1996, 42(1):49-54.
40. Sweitzer M.M., Donny E.C., Hariri A.R. Imaging genetics and the neurobiological basis of individual differences in vulnerability to addiction. Drug Alcohol Depend. 2012, 123(Suppl. 1):S59-S71.
41. Swendsen J., Ben-Zeev D., Granholm E. Real-time electronic ambulatory monitoring of substance use and symptom expression in schizophrenia. Am. J. Psychiatry 2011, 168(2):202-209.
42. Whitfield-Gabrieli S., Ford J. Default mode network activity and connectivity in psychopathology. Annu. Rev. Clin. Psychol. 2011, 8. (18-18:21).
43. Whitfield-Gabrieli S., Nieto-Castanon A. Conn: a functional connectivity toolbox for correlated and anticorrelated brain networks. Brain Connect. 2012, 2(3):125-141.
44. Zammit S., Moore T.H., Lingford-Hughes A., Barnes T.R., Jones P.B., Burke M., Lewis G. Effects of cannabis use on outcomes of psychotic disorders: systematic review. Br. J. Psychiatry 2008, 193(5):357-363.
45. Zimmet S.V., Strous R.D., Burgess E.S., Kohnstamm S., Green A.I. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J. Clin. Psychopharmacol. 2000, 20(1):94-98.